Seed17 November 2025

1nhaler secures £1.5m in seed follow-on funding led by Archangels to advance its paper inhaler platform

The financing will support clinical material manufacture and preparation for regulatory studies ahead of a target marketing authorisation application.

£1.5MSeed

1nhaler develops a single-dose dry powder inhaler made predominantly from cardboard. The credit card sized device uses a patented membrane system to deliver medications sustainably.

Edinburgh-based drug delivery device developer 1nhaler has secured £1.5m in seed follow-on funding to advance its paper inhaler platform. The round was led by Archangels, with additional participation from Scottish Enterprise and BBB Investments.

The fresh capital will be directed towards manufacturing clinical materials for regulatory studies, designing large-scale commercial manufacturing processes, and targeting a first Marketing Authorisation Application by late 2027. This follows a previous £2m raise in 2023, also backed by Archangels.

1nhaler's single-dose dry powder inhaler offers an eco-friendly alternative to bulky plastic devices. The credit card sized, flat-pack design transforms into a three-dimensional inhaler, aiming to reduce costs and environmental impact while matching the performance of established multidose devices.

From the founder

"This additional funding represents strong continued confidence in our technology platform and our progress towards commercialisation. The support from Archangels, Scottish Enterprise and BBB Investments is enabling us to advance our clinical and manufacturing capabilities as we work towards regulatory approval."

Lisa McMyn

Chief Executive Officer at 1nhaler

Investor perspective

"We’re delighted to continue supporting 1nhaler as they make good progress towards bringing their disruptive technology platform to market. The team has demonstrated strong technical validation and is building meaningful commercial partnerships across multiple therapeutic areas."